We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current BCLI market cap is 12.66M. The company's latest EPS is USD and P/E is N/A.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -5.45M | -6.04M | -4.8M | -2.47M | -2.98M |
| Net Income | -5.33M | -1.23M | -5.58M | -3.4M | -2.54M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -23M | -31.68M | -24.54M | -24.82M | -21.44M |
| Net Income | -23.25M | -31.81M | -24.46M | -24.28M | -17.19M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 5.75M | 5.68M | 4.21M | 3.35M | 5.68M |
| Total Liabilities | 9.63M | 8.26M | 9.07M | 8.9M | 9.21M |
| Total Equity | -3.88M | -2.58M | -4.86M | -5.55M | -3.53M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 6.53M | 51.26M | 29.28M | 8.45M | 4.21M |
| Total Liabilities | 18.76M | 15.8M | 9.94M | 11.47M | 9.07M |
| Total Equity | -12.22M | 35.46M | 19.34M | -3.02M | -4.86M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -10.76M | -17.17M | -20.46M | -3.06M | -4.75M |
| Investing | 2.01M | 2M | 2.19M | N/A | N/A |
| Financing | 8.53M | 15.63M | 18.98M | 2.54M | 6.91M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -11.25M | -35.19M | -26.27M | -19.32M | -20.46M |
| Investing | 5.62M | -4.45M | 323k | 998k | 2.19M |
| Financing | 5.23M | 76.94M | 6.97M | 238k | 18.98M |
| Market Cap | 12.66M |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 5.7M |
| Average Volume (1 week) | 227.03k |
| Average Volume (1 Month) | 129.08k |
| 52 Week Change | -38.87% |
| 52 Week High | 11.8905 |
| 52 Week Low | 1.05 |
| Spread (Intraday) | 0.07 (3.15%) |
| Company Name | Brainstorm Cell Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.brainstorm-cell.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
